Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wynzora (MC2-01) Cream vs Vehicle and Active Comparator in Psoriasis
NCT03308799Phase 3
Key facts
- Status
- Completed
- Start
- Oct 2017
- Primary completion
- Jun 2018
- Countries
- 1
- Sponsor
- MC2 Therapeutics
- Modality
- Small Molecules
- Conditions
- Psoriasis vulgaris (PV)
01
Overview
Phase 3, randomised, single-blind trial of calcipotriol + betamethasone in Psoriasis vulgaris (PV) (3 arms), sponsored by MC2 Therapeutics. Primary endpoint: Physicians Global Assessment Treatment Success at 8 weeks. Started Oct 2017; status: completed.
02
Design
3 arms- Study design
- RandomizedSingle-blind
MC2-01 Cream
Wynzora (calcipotriene/betamethasone dipropionate) cream once daily
Cal/BDP combination
Active comparator (Taclonex) once daily
Cream vehicle
Vehicle cream once daily
03
Who it enrols
Adult patients with mild-to-moderate plaque psoriasis (PGA mild/moderate, mPASI >= 2, BSA 2-30%) of at least 6 months duration.
04
Endpoints
Primary
Physicians Global Assessment Treatment Success
Secondary
Percentage Change in Modified Psoriasis Area and Severity Index Score
Psoriasis Treatment Convenience Scale
Beyond the preview
Go deeper on NCT03308799.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308799.